Free Trial
NASDAQ:VRTX

Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

$481.89
+7.32 (+1.54%)
(As of 07/8/2024 ET)
Today's Range
$472.00
$483.00
50-Day Range
$392.81
$485.53
52-Week Range
$339.02
$486.42
Volume
774,556 shs
Average Volume
1.14 million shs
Market Capitalization
$124.35 billion
P/E Ratio
31.27
Dividend Yield
N/A
Price Target
$448.61

Vertex Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.54 Rating Score
Upside/​Downside
6.9% Downside
$448.61 Price Target
Short Interest
Bearish
1.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.12
Upright™ Environmental Score
News Sentiment
1.04mentions of Vertex Pharmaceuticals in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$13.06 M Sold Last Quarter
Proj. Earnings Growth
5.37%
From $15.08 to $15.89 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.85 out of 5 stars

Medical Sector

192nd out of 876 stocks

Pharmaceutical Preparations Industry

79th out of 416 stocks

VRTX stock logo

About Vertex Pharmaceuticals Stock (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated, an American biopharmaceutical company headquartered in Boston, Massachusetts, was founded in 1989 by Joshua Boger and Kevin J. Kinsella with a vision to revolutionize disease treatments through rational drug design. Their mission is to "transform the way serious diseases are treated," and they have made significant strides in achieving this goal. The company specializes in researching, developing, and commercializing innovative therapies for various medical conditions, primarily focusing on cystic fibrosis. Using cutting-edge science and technology, Vertex has become a leading player in the biotech industry, particularly in the field of precision medicine.

Vertex has overcome challenges and achieved milestones, chronicled in Barry Werth's book "The Billion-Dollar Molecule." Over the years, the company's research and development efforts have primarily targeted viral infections, inflammatory and autoimmune disorders, cancer, and other specialty diseases. Vertex's flagship products are dedicated to treating cystic fibrosis, a genetic condition affecting the respiratory and digestive systems. Notable among these are Kalydeco, the first FDA-approved drug addressing the underlying cause of cystic fibrosis for specific gene mutations, Orkambi, a combination drug for patients with the most common cystic fibrosis mutation (F508del), Symdeko, a dual combination treatment for certain gene mutations and Trikafta, a groundbreaking triple-combination therapy for cystic fibrosis.

The company's target market consists of patients suffering from serious diseases, especially those with cystic fibrosis and other genetic disorders. Vertex's therapies are designed to cater to specific gene mutations, offering personalized and precision medicine approaches. Key customers include patients with cystic fibrosis and their families, healthcare providers specializing in genetic diseases and health systems, and insurers providing access to these life-changing therapies. Vertex Pharmaceuticals has achieved significant financial growth in recent years, reflecting its successful drug development efforts. Impressive revenue metrics and robust earnings metrics indicate the company's ability to translate its research into profitable treatments efficiently. The company's strong profit margin metrics also showcase its effective financial management.

The positive financial performance has driven the company's stock price upwards, reflecting investor confidence in Vertex's ability to deliver innovative therapies and capitalize on unmet medical needs. The company's strong financials, expanding product pipeline, and contributions to cystic fibrosis treatment have justified its favorable valuation compared to industry peers. Vertex Pharmaceuticals' successful development and commercialization of Trikafta have been key drivers behind the company's positive valuation and investor sentiment. The drug's significant impact on patients and its potential for continued growth have attracted investors seeking exposure to the dynamic biopharmaceutical sector.

As Vertex explores gene-editing therapies in collaboration with CRISPR Therapeutics and Arbor Biotechnologies, investors view the company as a strategic player in addressing significant unmet medical needs. The company's commitment to research and development further solidifies investor confidence in its long-term prospects.

Vertex Pharmaceuticals has demonstrated resilient stock performance. Investors recognize the company's value as a pioneer in the biotech industry, with a focus on precision medicine and transformative therapies. The company's dedication to research and its successful commercialization of existing drugs underscores its strategic positioning in the market.

As Vertex continues to expand its product pipeline and explore new treatment avenues, investors remain optimistic about the company's growth potential. The company's innovative research collaborations, particularly in gene-editing therapies, are expected to drive further positive investor sentiment. In the broader industry, Vertex Pharmaceuticals is well-positioned relative to its peers. Its specialization in precision medicine and groundbreaking therapies for genetic diseases sets it apart, giving the company a competitive advantage. Vertex's successful track record and commitment to addressing unmet medical needs further reinforce its strong position in the market.

While Vertex Pharmaceuticals has achieved significant milestones, the company faces certain risks and challenges. Regulatory hurdles, competitive pressures, and the need for continued investment in research and development are potential factors that may impact its future growth. However, the company's risk management strategies and prudent financial management are designed to mitigate potential risks and position Vertex for continued success. As the company continues to innovate and expand its product portfolio, it is expected to maintain its strong position in the biopharmaceutical industry.

VRTX Stock Price History

VRTX Stock News Headlines

Amgen sign at biopharmaceutical company office
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex (VRTX)
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout.
Does this make you sick?
The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.
3 No-Brainer Stocks to Buy in July
3 Pharma Stocks Already Ushering in the Next Biotech Boom
The 3 Best Biotech Stocks to Buy in July 2024
Does this make you sick?
The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.
See More Headlines
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/06/2024
Today
7/08/2024
Next Earnings (Confirmed)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VRTX
CUSIP
92532F10
Employees
5,400
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$448.61
High Stock Price Target
$555.00
Low Stock Price Target
$325.00
Potential Upside/Downside
-6.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.54
Research Coverage
26 Analysts

Profitability

Net Income
$3.62 billion
Pretax Margin
46.81%

Debt

Sales & Book Value

Annual Sales
$9.87 billion
Cash Flow
$14.88 per share
Book Value
$68.22 per share

Miscellaneous

Free Float
257,537,000
Market Cap
$124.35 billion
Optionable
Optionable
Beta
0.39

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

  • Vertex Pharmaceuticals stock price has been steadily increasing, reaching $480.73 on the latest trading day, indicating positive momentum.
  • Vertex Pharmaceuticals reported strong quarterly earnings results, surpassing analysts' expectations with $4.76 EPS and revenue of $2.69 billion.
  • The company has a solid return on equity of 23.08%, showcasing efficient utilization of shareholder funds.
  • Vertex Pharmaceuticals focuses on developing and commercializing therapies for treating cystic fibrosis, a niche market with high demand for innovative treatments.
  • Analysts have upgraded Vertex Pharmaceuticals' stock rating to a "strong-buy," indicating favorable outlook and potential for further growth.

Cons

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

  • Vertex Pharmaceuticals stock has a relatively high price-to-earnings ratio of 31.20, which may indicate an overvalued position compared to industry peers.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, June 30, 2024. Please send any questions or comments about these Vertex Pharmaceuticals pros and cons to contact@marketbeat.com.

VRTX Stock Analysis - Frequently Asked Questions

How have VRTX shares performed this year?

Vertex Pharmaceuticals' stock was trading at $406.89 at the start of the year. Since then, VRTX stock has increased by 18.4% and is now trading at $481.89.
View the best growth stocks for 2024 here
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings data on Monday, May, 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals's quarterly revenue was up 13.3% on a year-over-year basis.
Read the conference call transcript
.

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

Does Vertex Pharmaceuticals have any subsidiaries?

Vertex Pharmaceuticals subsidiaries include V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and more.

Who are Vertex Pharmaceuticals' major shareholders?

Top institutional investors of Vertex Pharmaceuticals include DNB Asset Management AS (0.06%), Boston Common Asset Management LLC (0.01%), Moody National Bank Trust Division and First Hawaiian Bank. Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Charles F Wagner Jr, Bruce I Sachs, Bastiano Sanna, David Altshuler, Carmen Bozic, Jeffrey M Leiden, Edward Morrow Atkinson III, Jonathan Biller, Kristen Ambrose, Joy Liu, Sangeeta N Bhatia, Yuchun Lee and Margaret G Mcglynn.
View institutional ownership trends
.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU) and Salesforce (CRM).

This page (NASDAQ:VRTX) was last updated on 7/9/2024 by MarketBeat.com Staff

From Our Partners